Norway-based clinical-stage biopharmaceutical company BerGenBio ASA (OSE: BGBIO) on Monday announced preliminary safety data from the Phase 1b portion of its BGBC016 study in first-line Non-Small Cell Lung Cancer (NSCLC) patients.

The study assessed three escalating doses of bemcentinib, a selective AXL kinase inhibitor, in combination with standard chemo-immunotherapy, doublet chemotherapy and pembrolizumab (Keytruda). The primary endpoint focused on safety, with results showing the combination was well tolerated across all doses with no new safety signals. No dose-related electrocardiographic changes (QTc) were observed.

Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, consistent with previous responder data from the BGBC008 study in second-line NSCLC patients. These findings support further development of bemcentinib in combination with chemo-immunotherapy for advanced NSCLC.